Alyssum Therapeutics Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$28M
- Investors
-
10
Alyssum Therapeutics General Information
Description
Developer of supramolecular therapeutics designed for cancer patients. The company offers treatments and antibody drugs to treat lung, testicular, colorectal, and childhood cancers, its therapeutics use supra-molecular technology to design anti-cancer drugs that home in on the tumor and modulate the tumor immune response, enabling oncologists to outsmart cancer cells in patients by activating the immune system.
Contact Information
Website
www.alyssumtx.comCorporate Office
- 626 Massachusetts Avenue
- 2nd floor
- Cambridge, MA 02139
- United States
Corporate Office
- 626 Massachusetts Avenue
- 2nd floor
- Cambridge, MA 02139
- United States
Alyssum Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series A) | 08-Jan-2025 | $28M | Completed | Clinical Trials - Phase 1 | ||
| 5. Later Stage VC | 29-Oct-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Secondary Transaction - Private | 01-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 28-Mar-2017 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 08-Feb-2016 | $1.92M | Completed | Clinical Trials - Phase 1 | ||
| 1. Early Stage VC (Series A) | 28-May-2013 | $1.92M | $1.92M | Completed | Product Development |
Alyssum Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| CCPS | ||||||||
| Preference | ||||||||
| CCPS | 5,000 | $0.151382 | $151.38 | $151.38 | 1x | $151.38 | 6.99% | |
| Preference | 5,000 | $0.151382 | $151.38 | $151.38 | 1x | $151.38 | 6.99% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Alyssum Therapeutics Comparisons
Industry
Financing
Details
Alyssum Therapeutics Competitors (27)
One of Alyssum Therapeutics’s 27 competitors is IFM Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| IFM Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Gamida Cell | Formerly VC-backed | Boston, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Auron Therapeutics | Venture Capital-Backed | Newton, MA |
Alyssum Therapeutics Patents
Alyssum Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12357699-B2 | B-cell immunotherapy in cancer treatment | Active | 10-Jul-2018 | ||
| WO-2018146641-A1 | Novel inhibitors of cellular signalling | Inactive | 11-Feb-2017 | ||
| WO-2018009527-A1 | Evaluation and optimization of supramolecular therapeutics | Inactive | 05-Jul-2016 | ||
| WO-2017199201-A1 | Crystalline platinum-based compounds | Inactive | 18-May-2016 | ||
| AU-2017218772-A1 | Cellular signalling inhibitors, their formulations and methods thereof | Inactive | 11-Feb-2016 | A61K47/554 |
Alyssum Therapeutics Signals
Alyssum Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Famy (India) | Corporation | Minority | ||
| Angel (individual) | Minority | |||
| FemHealth Ventures | Venture Capital | Minority | ||
| Accel | Venture Capital | Minority | ||
| REMUS Capital | Venture Capital | Minority |
Alyssum Therapeutics FAQs
-
When was Alyssum Therapeutics founded?
Alyssum Therapeutics was founded in 2011.
-
Where is Alyssum Therapeutics headquartered?
Alyssum Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Alyssum Therapeutics?
Alyssum Therapeutics has 4 total employees.
-
What industry is Alyssum Therapeutics in?
Alyssum Therapeutics’s primary industry is Drug Discovery.
-
Is Alyssum Therapeutics a private or public company?
Alyssum Therapeutics is a Private company.
-
What is Alyssum Therapeutics’s current revenue?
The current revenue for Alyssum Therapeutics is .
-
How much funding has Alyssum Therapeutics raised over time?
Alyssum Therapeutics has raised $32.7M.
-
Who are Alyssum Therapeutics’s investors?
Famy (India), , FemHealth Ventures, Accel, and REMUS Capital are 5 of 10 investors who have invested in Alyssum Therapeutics.
-
Who are Alyssum Therapeutics’s competitors?
IFM Therapeutics, Inovio Pharmaceuticals, Gamida Cell, Kite Pharma, and Auron Therapeutics are some of the 27 competitors of Alyssum Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process